This was always going to be a tough comparable, given the NT-proBNP licence expiration. However, Bioventix delivered a very credible set of interims given the ongoing impact of COVID-19 on the broader IVD market. Revenues declined 8% (£0.4m), resulting in an adjusted pre-tax profit and adjusted EPS falling 4% (£0.15m) to £3.6m and 59.3p, respectively. Stripping out the NT-proBNP effect, the underlying strength of the business is reflected in 4% revenue and 13% adjusted PBT growth. An interim div ....
28 Mar 2022
Bioventix - Interims – evidence of strong underlying performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioventix - Interims – evidence of strong underlying performance
Bioventix Plc (BVXP:LON) | 4,450 0 0.0% | Mkt Cap: 232.3m
- Published:
28 Mar 2022 -
Author:
Mark Brewer -
Pages:
14
This was always going to be a tough comparable, given the NT-proBNP licence expiration. However, Bioventix delivered a very credible set of interims given the ongoing impact of COVID-19 on the broader IVD market. Revenues declined 8% (£0.4m), resulting in an adjusted pre-tax profit and adjusted EPS falling 4% (£0.15m) to £3.6m and 59.3p, respectively. Stripping out the NT-proBNP effect, the underlying strength of the business is reflected in 4% revenue and 13% adjusted PBT growth. An interim div ....